PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Cerulean Associates, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Cerulean Publishes Strategy to Cut Supplier Risk for Biopharmaceutical and Device Companies - Cerulean has published another section of its Lean Compliance strategy for pharmaceutical, biotechnology and medical device firms, this one focused on minimizing supply chain risk and maximizing return on investment
Cerulean Publishes Strategy to Cut Supplier Risk for Biopharmaceutical and Device Companies

 

NewswireToday - /newswire/ - Williamsburg, VA, United States, 2008/04/14 - Cerulean has published another section of its Lean Compliance strategy for pharmaceutical, biotechnology and medical device firms, this one focused on minimizing supply chain risk and maximizing return on investment.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Compliance directors, CFOs and quality managers now have a proven strategy to control risks associated with their supply chain according to a new article published in the March edition of the peer-reviewed BioProcess International journal, “Shared Risk: A Regulatory Management Strategy.”

Part of Cerulean’s Lean Compliance strategy, the article uses client case studies and the personal experiences of Cerulean’s co-founder, John Avellanet, a former medical device executive, to discuss several core tactics to Cerulean’s Lean Compliance approach when it comes to vendor selection and management:
1. Strategic supplier selection using Cerulean’s Strategy-Impact Matrix
2. Contractual tactics
3. Mistakes to avoid (that often seem like good ideas at first)

“Given the entire Heparin mess, we decided to publish the strategy to give executives a chance to adopt this and quickly achieve a peace of mind,” said Mr. Avellanet. “In fact, I’ve recently been asked to serve on an FDA panel in September to discuss ways to more broadly apply this across the pharmaceutical and biotech industries.”

For non-BioProcess International subscribers, Cerulean will make a free reprint of the article available next month in the Resource Library of the Cerulean website.

Mr. Avellanet is an internationally recognized expert, business adviser and syndicated author on cost-effective regulatory compliance. He publishes the monthly executive newsletter SMARTERCOMPLIANCE™, and is the compliance columnist for the international Journal of Commercial Biotechnology.

Cerulean Associates LLC (ceruleanllc.com) is a small, private compliance consulting company that helps clients achieve cost-effective lean compliance, prevent intellectual property theft and streamline their quality systems.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Cerulean Associates, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Cerulean Publishes Strategy to Cut Supplier Risk for Biopharmaceutical and Device Companies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: John Avellanet - CeruleanLLC.com 
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cerulean Associates, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Cerulean Associates, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)